Recombinant antibody production has emerged as a potent and ground-breaking technology in biomedical research. It has completely transformed the way scientists and researchers study illnesses, create ...

Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...

Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

The antibody therapeutics industry is growing at an incredible pace. From early monoclonal therapeutic antibodies to modern bispecific and multispecific antibodies, single domain antibodies (VHHs), ...

Recombinant antibodies offer clear advantages over conventional polyclonal and hybridoma-derived antibodies by providing sequence-defined, renewable, and highly reproducible reagents. Their use ...

C1 Monoclonal Antibody Progress for RSV and Malaria Following Full $3.1 Million Gates Foundation Grant FundingJUPITER, Fla., ...

First antibody-drug conjugate facility to receive three provincial regulatory approvals for segmented manufacturing.Demonstrated a unified quality system, strict risk assessment protocols, and ...

A recombinant protein is a protein made by genetically engineered cells rather than extracted directly from its natural source. Scientists insert the gene for the desired protein into a production ...

Mass production of recombinant proteins using yeast cell "factories" needs methanol, a compound that requires safe handling, carries the risk of catching fire, and sometimes produces harmful ...